With the goal of raising the quality and accessibility of its healthcare system to a level commensurate with its position as the world’s second-largest economy, the Chinese government has in the past five years doubled the money it pours into public hospitals... Read More
Despite renewed government efforts to bring South Korea’s historically elevated rate of tuberculosis under control, the nation still has the highest incidence rate of the disease among the world’s wealthiest countries – nations that belong to the 34-member Organization for Economic Cooperation and... Read More
Spiraling trade tensions between the U.S. and China are injecting uncertainty into what was already a complex environment for MedTech manufacturers. Accelerating steps, some medical technology firms have already been starting to move their operations to other countries in the region. Directly... Read More
China’s ambitious campaign to expand healthcare coverage and access to innovative drugs is making its pharmaceutical market an increasingly key source of growth for foreign firms. But even as the more than $135 billion pharmaceutical markets in the Asian giant surpasses that... Read More
Spending on cancer drugs is dominating health spending in China, with hospitals in 2018 purchasing more cancer and immunomodulatory drugs than anti-infective drugs for the first time ever. According to data from the China Pharmaceutical Association (CPA), anti-tumor and immunomodulatory treatments represented... Read More
Fueled by high sugar diets, processed food, misinformation and a dearth of early intervention, the prevalence of Type 2 diabetes is a persistent public health crisis in Southeast Asia. One of every 14 people in Indonesia, Malaysia, Singapore, and Thailand has some... Read More
This article was originally published on Medtech Intelligence. Precision medicine, an emerging toolkit of ways to better understand the complex mechanisms underlying a patient’s health, disease, or condition, and to better predict which treatments will be most effective, has grown unevenly outside... Read More
Stymied by what they say is overzealous regulation, India’s’ drug companies are increasingly lobbying the government to reduce oversight of clinical trials, ease limits on new pharmaceutical ventures, and reduce regulations on new drugs. Pharma firms in India are big business. Currently... Read More
A new free trade agreement between Vietnam and the European Union grants foreign pharmaceutical companies the right to import drugs to this fast-growing Southeast Asian nation. Under the terms of the pact signed several months ago, foreign pharmaceutical companies designated as foreign... Read More
With clinical research and regulatory filings booming in China, regulatory authorities are receiving a record number of drug applications for new clinical trials and drug approvals. Last year, more than 5,500 applications for technical review were filed with China’s Center for Drug... Read More